<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03806582</url>
  </required_header>
  <id_info>
    <org_study_id>TPO 1051</org_study_id>
    <nct_id>NCT03806582</nct_id>
  </id_info>
  <brief_title>Effect of a Higher Blood-pressure on Right Ventricular Function</brief_title>
  <official_title>Effect of a Higher Blood-pressure on Right Ventricular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Centre Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Centre Leeuwarden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Right ventricular (RV) dysfunction in cardiac surgery is an independent risk factor for
      morbidity and mortality. Raising the systemic blood pressure with norepinephrine seems to
      have a positive influence on the right ventricular function in several animal studies. The
      current study is designed to evaluate the effect of a higher blood pressure on the RV
      function in post cardiac surgery patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Goal: To demonstrate differences in RV function by raising the systemic blood pressure with
      norepinephrine.

      Study design: randomized controlled trial Study population: 78 postoperative cardiac surgery
      patients admitted at the ICU.

      Intervention:

        -  Group 1: (N=22): RVEF&lt;20% and MAP≤65mmHg. Intervention with norepinephrine to reach a
           MAP of 85mmHg for a maximum duration of two hours.

        -  Group 2: (N=22): RVEF &lt;20% and MAP≤65mmHg. Control group: treatment according to current
           standards. Hypotensive patients are treated with fluids and/or vasopressors to gain a
           mean arterial pressure (MAP) of 65mmHg.

        -  Group 3: (N=17): RVEF between ≥20 and &lt;30% and MAP ≤65mmHg. Intervention with
           norepinephrine to reach a MAP of 85mmHg for a maximum duration of two hours.

        -  Group 4: (N=17): RVEF between ≥20 and &lt;30% and MAP ≤65mmHg. Control group: treatment
           according to current standards. Hypotensive patients are treated with fluids and/or
           vasopressors to gain a mean arterial pressure (MAP) of 65mmHg.

      Endpoints: Primary endpoint is the difference between the intervention and the control group
      in the change over time between baseline and the end of the study period (T4) in RVEF.
      Secondary endpoints are the echocardiographic parameters of RV and LV contractility, RV
      end-diastolic pressure, cardiac index, and fluid balance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>right ventricular ejection fraction</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Primary endpoint is the difference between the intervention and the control group in the change over time between baseline and the end of the study period (T4) in RVEF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Echocardiographic parameters of RV and LV contractility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV end-diastolic pressure</measure>
    <time_frame>baseline and 15 minutes postoperatively</time_frame>
    <description>RV end-diastolic pressure pre and post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Difference in cardiac index between intervention and control groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid balance</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Difference in fluid balance between intervention and control groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Blood Pressure</condition>
  <condition>Right Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group; treatment according to current standards, observation of the effect on right ventricular function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>intervention with norepinephrine to reach a MAP of 85 mmHg</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post operative cardiac surgery patients, full sternotomy

          -  admission at ICU

          -  informed consent

          -  right ventricular monitoring by pulmonary artery catheter.

          -  RVEF &lt;30% + MAP ≤ 65mmHg

        Exclusion Criteria:

          -  no informed consent

          -  acute surgery

          -  Off pump cardiac surgery

          -  Severe tricuspid insufficiency

          -  Allergy to norepinephrine

          -  Severe left ventricular hypertrophy with systolic anterior movement

          -  Chronic use of alpha-blockers

          -  Irregulair heart rhythm

          -  Surgical reasons to maintain a low blood pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiaan Boerma, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Centre Leeuwarden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8904 BR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Centre Leeuwarden</investigator_affiliation>
    <investigator_full_name>E.C. Boerma</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Right</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

